Tiziana Life Sciences
Tiziana Life Sciences
TLSA
NASDAQ
1.48
USD
0.00%
About
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201).
Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 253.8K |
| Three Month Average Volume | 6.0M |
| High Low | |
| Fifty-Two Week High | 1.74 USD |
| Fifty-Two Week Low | 0.41 USD |
| Fifty-Two Week High Date | 12 Aug 2024 |
| Fifty-Two Week Low Date | 15 Apr 2024 |
| Price and Volume | |
| Current Price | 1 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.23% |
| Thirteen Week Relative Price Change | -6.56% |
| Twenty-Six Week Relative Price Change | 93.51% |
| Fifty-Two Week Relative Price Change | 9.77% |
| Year-to-Date Relative Price Change | 50.80% |
| Price Change | |
| One Day Price Change | -7.41% |
| Thirteen Week Price Change | 0.01% |
| Twenty-Six Week Price Change | 112.77% |
| Five Day Price Change | -18.03% |
| Fifty-Two Week Price Change | 37.55% |
| Year-to-Date Price Change | 78.57% |
| Month-to-Date Price Change | -6.54% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.0537 USD |
| Book Value Per Share (Most Recent Quarter) | 0.0537 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.0537 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.0537 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.17457 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.17264 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.17264 USD |
| Normalized (Last Fiscal Year) | -0.17264 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.17264 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.17264 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.17264 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.17264 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.01148 USD |
| Cash Per Share (Most Recent Quarter) | 0.01148 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.17171 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.17171 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.15319 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 47.53% |
| Tangible Book Value (5 Year) | 60.22% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -4.44% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 14.64% |
| EPS Change (Trailing Twelve Months) | -15.39% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 19 |
| Price to Tangible Book (Most Recent Quarter) | 19 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -936,000 |
| Net Debt (Last Fiscal Year) | -936,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 19 |
| Price to Book (Most Recent Quarter) | 19 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 2 |
| Long Term Debt to Equity (Most Recent Quarter) | 2 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -15,698,000 |
| Free Cash Flow (Trailing Twelve Months) | -15,698,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 4 |
| Total Debt to Equity (Most Recent Quarter) | 4 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -91.52% |
| Return on Assets (Trailing Twelve Months) | -91.52% |
| Return on Assets (5 Year) | -58.16% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -140.92% |
| Return on Equity (Trailing Twelve Months) | -140.92% |
| Return on Equity (5 Year) | -76.07% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -138.98% |
| Return on Investment (Trailing Twelve Months) | -138.98% |
| Return on Investment (5 Year) | -75.36% |